70
Participants
Start Date
October 31, 2010
Primary Completion Date
November 28, 2016
Study Completion Date
November 28, 2016
adalimumab
Subcutaneous, 40 mg every other week for 4 weeks
Placebo
Subcutaneous, every other week for 4 weeks
Dep of Rheumatology, Stockholm
MR Centre, Dep of Clinical Neuroscience, Stockholm
Collaborators (1)
Abbott
INDUSTRY
Swedish Foundation for Strategic Research
OTHER
The Swedish Research Council
OTHER_GOV
Karolinska Institutet
OTHER